Ropes & Gray represented Coherus BioSciences, Inc. in a $1.1 billion immune-oncology collaboration agreement with Junshi Biosciences directed towards the development and commercialization of Junshi’s programmed cell death protein (anti-PD-1) monoclonal antibody, toripalimab, in the United States and Canada. Under the terms of the agreement, Coherus received a license for toripalimab, two option programs, and first negotiation rights to two early-stage checkpoint inhibitor antibodies. The transaction was announced on February 1.
The Ropes & Gray team was led by life sciences licensing and collaborations partner Hannah Freeman (Boston) and IP transactions associate Jimmy Chen (San Francisco) and included capital markets partner Zachary Blume, IP transactions partner David McIntosh (both of Boston), and litigation & enforcement partner Ama Adams (Washington, D.C.).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.